OTC:HOOK
HOOKIPA Pharma Inc.
A clinical-stage biotech firm advancing novel oncology therapeutics with a substantial R&D investment and strong cash position.
Key Metrics
Investment Thesis
Bull Case
Investors may view HOOKIPA as a high-potential turnaround candidate given its revenue growth from $14.2M in 2022 to $43.9M in 2024 and a narrowing net loss trend over the last three years. The company maintains a healthy current ratio with $80.7M in current assets against only $24.7M in liabilities, providing a buffer for future clinical milestones.
Bear Case
The stock carries substantial risk due to a cumulative retained earnings deficit of -$412.8M and negative operating cash flow that has depleted the beginning cash balance from $117.5M to ending levels near $39.9M. Without approved products generating commercial revenue, the company remains dependent on continuous fundraising to sustain its expensive research and development efforts.
About HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics primarily for oncology and other serious diseases. The firm operates within the highly competitive pharmaceutical industry, leveraging its extensive research and development pipeline to target unmet medical needs. With significant cash reserves relative to recent burn rates, the company continues to fund its proprietary drug discovery and development programs.
Analysis
Management Discussion
The company reported a net loss of $43.5M in 2024 compared to losses of $64.9M in 2022 and $81.6M in 2023, suggesting an improving bottom line trajectory despite elevated operational expenses. While revenue surged to $43.9M from $20.1M the prior year, the operating cash flow deficit remains severe at -$77.0M, driven by massive non-cash adjustments of -$2.3M and significant working capital changes.
Industry Overview
The global pharmaceutical industry is characterized by long development cycles, high failure rates in drug trials, and intense competition for regulatory approval. Biotech firms like HOOKIPA typically operate with thin profit margins until product launch, relying heavily on intellectual property protection and strategic partnerships to navigate this landscape.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $14.2M | $20.1M | $43.9M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $14.2M | $20.1M | $43.9M |
| Operating Expenses | $87.4M | $117.8M | $95.4M |
| Operating Income | $-73.2M | $-97.7M | $-51.5M |
| R&D | $68.6M | $86.4M | $68.5M |
| G&A | $18.8M | $18.6M | $20.2M |
| Stock-Based Comp | $5.0M | $2.3M | $2.0M |
| D&A | $3.6M | $3.6M | $2.8M |
| Depreciation | $1.9M | $2.0M | $400.0K |
| Other OpEx | $0 | $12.8M | $6.7M |
| Non-Operating Income | $8.5M | $16.5M | $7.8M |
| Interest Expense | $687.0K | $317.0K | — |
| Interest Income | $1.6M | $5.3M | $3.7M |
| Pre-Tax Income | $-64.7M | $-81.2M | $-43.6M |
| Income Tax | $230.0K | $368.0K | $-106.0K |
| Continuing Ops | $-64.9M | $-81.6M | $-43.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-64.9M | $-81.6M | $-43.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-64.9M | $-81.6M | $-43.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $147.2M | $147.1M | $80.7M |
| Cash & Equivalents | $112.5M | $117.1M | $39.7M |
| Accounts Receivable | $6.5M | $511.0K | $290.0K |
| Prepaid Expenses | — | — | $15.0M |
| Other Current Assets | $28.2M | $29.5M | $25.7M |
| Long-Term Assets | $23.3M | $14.2M | $1.9M |
| PP&E (Net) | $18.0M | $7.7M | $179.0K |
| Operating Leases | $4.0M | $5.5M | $885.0K |
| Other LT Assets | $1.3M | $1.0M | $816.0K |
| Total Assets | $170.5M | $161.3M | $82.5M |
| Current Liabilities | $35.6M | $42.0M | $24.7M |
| Accounts Payable | $5.5M | $12.5M | $8.7M |
| Current Leases | $1.7M | $1.6M | $552.0K |
| Deferred Revenue | $15.7M | $14.6M | — |
| Taxes Payable | $230.0K | $367.0K | — |
| Other Current Liab | $12.5M | $12.9M | $15.4M |
| Long-Term Liabilities | $32.3M | $29.5M | $6.7M |
| LT Operating Leases | $2.3M | $3.8M | $323.0K |
| Other LT Liab | $4.3M | $6.0M | $6.4M |
| Total Liabilities | $67.9M | $71.5M | $31.3M |
| Shareholders' Equity | $102.5M | $89.9M | $51.2M |
| Paid-In Capital | $397.3M | $467.0M | $469.1M |
| Retained Earnings | $-287.7M | $-369.3M | $-412.8M |
| AOCI | $-7.2M | $-7.9M | $-5.1M |
| Total L&E | $170.5M | $161.3M | $82.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-64.9M | $-81.6M | $-43.5M |
| Non-Cash Adjustments | $11.5M | $31.2M | $-2.3M |
| Working Capital Changes | $33.4M | $-7.1M | $-31.2M |
| Cash from Operations | $-20.0M | $-57.5M | $-77.0M |
| Capital Expenditures | $5.0M | $4.2M | $194.0K |
| Cash from Investing | $-5.0M | $-4.2M | $-194.0K |
| Cash from Financing | $72.3M | $65.7M | $-1.3M |
| FX Effect | $-725.0K | $90.0K | $813.0K |
| Net Change in Cash | $47.3M | $4.0M | $-78.4M |
| Beginning Cash | $66.9M | $113.4M | $117.5M |
| Ending Cash | $113.4M | $117.5M | $39.9M |
Frequently Asked Questions
How does HOOKIPA Pharma Inc. make money?
Oncology Therapeutics Development, Early-Stage Drug Discovery, and Strategic Collaboration Partnerships for Novel Molecular Entities.
What are the main risks for HOOK?
Significant net loss of $43.5M in 2024 exacerbating the retained earnings deficit of $412.8M, heavy reliance on successful R&D outcomes given zero current product revenue, and limited operating cash flow of -$77.0M raising capital preservation concerns.
What is HOOK's competitive advantage?
Substantial cash on hand of $39.7M providing operational flexibility, high research and development expenditure of $68.5M indicating a robust pipeline focus, and a low cost of revenue structure typical of pre-revenue biotech firms.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.